Schulthess P., Post T.M., Yates J., Graaf P.H.v.d. Frequency-Domain Response Analysis for Quantitative Systems Pharmacology Models. CPT Pharmacometrics Syst Pharmacol: 111–123, 2018. [Link to publication]
Goto, A., Tagawa, Y., Moriya, Y., Sato, S., Yamamoto, M., Wakabayashi T., Tsukamoto T., Jongh J.d., Steeg T.J.v., Moriwaki T., Asahi, S. Influence of Body Composition on Disposition of the Highly Fat Distributed Compound as Analyzed by Physiologically-based Pharmacokinetic (PBPK) Modeling and Simulation. Biopharmaceutics & Drug Disposition: 543-552, 2017. [Link to publication]
Goto, A., Tagawa, Y., Moriya, Y., Sato, S., Furukawa, Y., Wakabayashi, T., Tsukamoto T., Jongh J.d, Steeg T.J.v., Moriwaki T., Asahi, S. Impact of acute fat mobilisation on the pharmacokinetics of the highly fat distributed compound TAK-357, investigated by physiologically based pharmacokinetic (PBPK) modeling and simulation. Biopharmaceutics & Drug Disposition, 373–380, 2017. [Link to publication]
Schulthess P., Post T.M., Yates J., Graaf H.J.v.d. Frequency-domain response analysis for quantitative systems pharmacology models. PAGE, 2017. [Link to publication]
Vis P., Snelder N., Ahsman M., MacLean D. and Faessel H., Optimization of trial design and dose selection based on the quantitative assessement of the efficacy of TAK-385. WCOP, (2016).
Snelder N. and Steeg T.v., QSP Modelling at the heart of the action. ACoP, (2016).
Snelder N., Ploeger B.A., Luttringer O., Stanski D.R. and Danhof M., Translational Pharmacokinetic Modeling of Fingolimod (FTY720) as a Paradigm Compound Subject to Sphingosine Kinase-mediated Phosphorylation, Drug Metab Dispos, 25(113): 056770, 2014. [Link to publication]
Maanen E.v., Ackaert O., Snelder N., Bergmann K., Maciag C., Quirk M., Wallsten C. and Ploeger B., Data transformation procedure to improve identifiability of efficacy and potency: Application to continuous elevated plus-maze data in rats., PAGE.(2012) [Link to publication]
Holford N., Ma S.C. and Ploeger B.A., Response to “validation and assessment of predictive performance in simulation models of clinical trials”, Clin Pharmacol Ther., 89(4): 488. Epub 2011 Feb 2023., 2011. [Link to publication]
Erp N.P.v., Guchelaar H.J., Ploeger B.A., Romijn J.A., Hartigh J. and Gelderblom H., Mitotane has a strong and a durable inducing effect on CYP3A4 activity, Eur J Endocrinol., 164(4): 621-626. Epub 2011 Jan 2010., 2011. [Link to publication]